SEC Filings

8-K
PERNIX THERAPEUTICS HOLDINGS, INC. filed this Form 8-K on 02/19/2019
Entire Document
 

 

51 ▪ First two months of U.S. net sales were the highest of 2018 YTD, with significant increases in revenue per unit sold ▪ In August 2018 , Nalpropion realized a ~ 46 % reduction in operating expenses vs. Orexigen forecast; realized positive EBITDA of $ 1.6 million Monthly Net Sales ($MM) & Net Revenue / Unit Nalpropion / Contrave ® Momentum (cont’d) $7 $5 $7 $6 $9 $5 $5 $8 $6 $8 $5 $3 $8 $8 $102 $80 $94 $95 $99 $91 $94 $96 $85 $100 $78 $69 $108 $101 $0 $20 $40 $60 $80 $100 $0.0 $1.0 $2.0 $3.0 $4.0 $5.0 $6.0 $7.0 $8.0 $9.0 $10.0 Aug-17 Sep-17 Oct-17 Nov-17 Dec-17 Jan-18 Feb-18 Mar-18 Apr-18 May-18 Jun-18 Jul-18 Aug-18 Sep-18 Net Revenue / Unit Monthly Net Sales ($MM) Net Sales Revenue / Unit